CU20110034A7 - THERAPEUTIC AGENTS 414 - Google Patents

THERAPEUTIC AGENTS 414

Info

Publication number
CU20110034A7
CU20110034A7 CU20110034A CU20110034A CU20110034A7 CU 20110034 A7 CU20110034 A7 CU 20110034A7 CU 20110034 A CU20110034 A CU 20110034A CU 20110034 A CU20110034 A CU 20110034A CU 20110034 A7 CU20110034 A7 CU 20110034A7
Authority
CU
Cuba
Prior art keywords
therapeutic agents
formula
glk
glucokinase
sequestration
Prior art date
Application number
CU20110034A
Other languages
Spanish (es)
Inventor
Christer Ralf Westerlund
Michael James Waring
Rolf Peter Walker
Henriksson Anette Marie Svensson
Volker Schnecke
Helen Claire Pointon
Ulrik Jurva
Jonas Rickard Fagerhag
Robert Darren Morse Davies
Leonie Campbell
Mikael Dan Brink
Peter Gustaf Bonn
Stuar Norman Lile Bennett
Graeme Richard Robb
Roger John Butlin
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to CU20110034A priority Critical patent/CU20110034A7/en
Publication of CU20110034A7 publication Critical patent/CU20110034A7/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un compuesto de fórmula (I): ESPACIO PARA LA FÓRMULA es útil en el tratamiento o prevención de una enfermedad o afección médica mediada por glucoquinasa (GLK o GK), que conduce a una reducción del umbral de glucosa para la secresión de insulina.A compound of formula (I): SPACE FOR FORMULA is useful in the treatment or prevention of a disease or medical condition mediated by glucokinase (GLK or GK), which leads to a reduction of the glucose threshold for insulin sequestration.

CU20110034A 2011-02-04 2011-02-04 THERAPEUTIC AGENTS 414 CU20110034A7 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CU20110034A CU20110034A7 (en) 2011-02-04 2011-02-04 THERAPEUTIC AGENTS 414

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU20110034A CU20110034A7 (en) 2011-02-04 2011-02-04 THERAPEUTIC AGENTS 414

Publications (1)

Publication Number Publication Date
CU20110034A7 true CU20110034A7 (en) 2011-12-28

Family

ID=45508742

Family Applications (1)

Application Number Title Priority Date Filing Date
CU20110034A CU20110034A7 (en) 2011-02-04 2011-02-04 THERAPEUTIC AGENTS 414

Country Status (1)

Country Link
CU (1) CU20110034A7 (en)

Similar Documents

Publication Publication Date Title
DOP2011000047A (en) THERAPEUTIC AGENTS 414
BR112014003198A2 (en) compounds for the treatment and prophylaxis of respiratory syncytial virus disease
EA201991014A1 (en) DIABETES TREATMENT
CO6821938A2 (en) A guanidine compound or salt thereof for the treatment of diseases related to vap -1
CR10564A (en) FUSIONATED CYCLIC COMPOUNDS
MX2013006113A (en) Bicyclic compound.
CR20120448A (en) HETEROCYCLIC COMPOUND
CR20130377A (en) DRUG METHODS AND PRODUCTS TO TREAT ALZHEIMER'S DISEASE
MX356728B (en) Pharmaceutical combination for use in the treatment of diabetes type 2.
CO6781497A2 (en) Treatment for lipodystrophy
PH12017500747B1 (en) Heterocyclic compound
MX2014002112A (en) Pyrimido- pyridazinone compounds and use thereof.
BR112015026238A2 (en) cancer treatment with dihydropyrazine pyrazines
DOP2012000058A (en) THERAPEUTIC AGENT FOR DISORDERS OF THE STATE OF ANIMO
BR112014011223A2 (en) method of treating a proliferative disease
MX349254B (en) Compounds for treatment of metabolic syndrome.
CL2011001943A1 (en) Antibiotic therapy to treat or prevent post-infectious irritable bowel syndrome.
MX2017003780A (en) PHARMACEUTICAL COMPOSITION TO TREAT ULCERATIVE COLITIS.
CR20110552A (en) TREATMENT OF INSULIN RESISTANT DISORDERS
BR112014008783A2 (en) compounds for the treatment and prophylaxis of respiratory syncytial virus disease
AR082278A1 (en) ENTEROVIRUS VACCINES TO PREVENT OR TREAT TYPE 1 DIABETES (III)
DOP2010000156A (en) OXAZOLIDINONES FOR THE TREATMENT AND / OR PROFILAXIS OF CARDIAC INSUFFICIENCY
DOP2012000056A (en) THERAPEUTIC AGENT FOR ANXIETY DISORDERS
UY32550A (en) "(2S) -2- [1- (2,6-DICLOROPHENYL) PIRAZOLO [4,5-E] PYRIMIDIN-4-IL] OXI-3- (3-HYDROXIAZETIDIN-1-IL) -N- (5- METHYLPIRAZIN-2-IL) PROPANAMIDE
MY182801A (en) Compound for activating ampk and uses thereof